CD99: A Key Regulator in Immune Response and Tumor Microenvironment

Area of Science:

• Immunology
• Cancer Biology
• Molecular Biology

Background:

• CD99 is a vital membrane protein involved in T-cell activation, apoptosis, and leukocyte movement.
• High CD99 expression in tumors correlates with cancer development, invasion, immune evasion, and drug resistance.
• CD99 functions at the nexus of normal physiology and pathological conditions like cancer.

Purpose of the Study:

• To review the multifaceted roles of CD99 in normal physiology and cancer.
• To explore the impact of anti-CD99 monoclonal antibodies on tumor-immune cell interactions and cancer treatment.
• To summarize how CD99 modulation affects cancer cell behavior and therapeutic efficacy.

Main Methods:

• Literature review of CD99's function in immunology and oncology.
• Analysis of studies on anti-CD99 antibody development and their mechanisms of action.
• Examination of CD99's influence on the tumor microenvironment and immune checkpoints.

Main Results:

• Anti-CD99 antibodies demonstrate efficacy in tumor elimination and immune cell recruitment.
• CD99 influences immune checkpoint molecules like CD47, suggesting combination therapy potential.
• Monoclonal antibodies targeting CD99 alter cancer cell interactions within their microenvironment.

Conclusions:

• CD99 is a critical regulator of immune cell function and cancer cell behavior.
• Anti-CD99 antibodies represent a promising therapeutic strategy for various cancers.
• Targeting CD99 offers potential for novel combination therapies with immune checkpoint inhibitors.